Literature DB >> 10149510

Clinical experience with heparin-coated cardiopulmonary bypass circuits.

M J Pradhan1, J S Fleming, U U Nkere, J Arnold, C R Wildlevuur, K M Taylor.   

Abstract

The extensive area of contact between blood and synthetic surfaces during cardiopulmonary bypass results in the activation of the kallikrein, the complement and the clotting and fibrinolytic systems. This results in white cell activation and a whole body inflammatory response. Pulmonary neutrophil sequestration is also known to occur during cardiopulmonary bypass and has been associated with pulmonary damage. This has been previously demonstrated using the technique of differential neutrophil counts in simultaneous venous and left atrial samples. The efficacy of retinal fluorescein angiography as an indicator of cerebral microembolism has also been proved in previous studies. The objectives of this study were to determine whether heparin precoating with Duraflo II reduced pulmonary neutrophil sequestration, retinal microembolism and postoperative blood loss. Fourteen patients were randomized into two groups using either heparin-coated or nonheparin-coated cardiopulmonary bypass circuits. The preliminary results suggest a reduction in pulmonary neutrophil sequestration (p greater than 0.05) and the generation of thrombin antithrombin complexes (p less than 0.05). Retinal microembolism was not significantly different in the two groups nor was the postoperative blood loss. Thus, heparin-coated cardiopulmonary bypass circuits do not reduce pulmonary neutrophil sequestration, retinal microembolism or postoperative blood loss.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 10149510     DOI: 10.1177/026765919100600313

Source DB:  PubMed          Journal:  Perfusion        ISSN: 0267-6591            Impact factor:   1.972


  1 in total

1.  Do surface-modifying additive circuits reduce the rate of cerebral microemboli during cardiopulmonary bypass?

Authors:  Rosendo A Rodriguez; Maura I Watson; Howard J Nathan; Fraser Rubens
Journal:  J Extra Corpor Technol       Date:  2006-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.